Industry

K.C. Pharmaceuticals recalls more than 3 million eye drop bottles

Healio Optometry3h ago1 min read

Editor’s note: This is a developing news story. Please check back soon for updates.K.C. Pharmaceuticals is recalling more than 3.1 million bottles of eye drops due to “lack of assurance of sterility,” according to the FDA.The eight affected products, totaling 3,111,072 individual units, have been distributed throughout the U.S.It is a class II recall, meaning the drops may cause temporary or reversible adverse effects, or have a low probability of causing severe adverse effects.The following products have been recalled:

Read full article on Healio Optometry

AI Summary

Quick Take

K.C. Pharmaceuticals has initiated a Class II recall of over 3.1 million bottles of eye drops across eight product lines due to a lack of assurance of sterility. The recall affects 3,111,072 individual units that were distributed nationwide, posing a risk of temporary or reversible adverse health effects.

Why It Matters

This massive recall adds to a growing list of sterility concerns involving over-the-counter ophthalmic products that have surfaced over the past year. While the Class II designation indicates a lower probability of severe or permanent harm compared to Class I events, any breach in sterility assurance is a critical safety issue for ocular health. Clinicians must be prepared to help patients identify these products, as many patients rely on generic or store-brand drops without tracking the specific manufacturer.

Key Details

The recall involves 3,111,072 individual units across eight different eye drop products.
The FDA has designated this as a Class II recall, meaning the products may cause temporary or reversible adverse effects.
The primary cause for the action is a 'lack of assurance of sterility' in the manufacturing or handling process.
Affected products were distributed throughout the entire United States.
This is currently a developing news story with further product-specific details expected.

Practice Implications

Eye care providers should screen patients for the use of generic or over-the-counter lubricants and advise them to discontinue any products associated with K.C. Pharmaceuticals until further notice. Patients presenting with unexpected ocular irritation or signs of infection should be questioned specifically about recent eye drop purchases and lot numbers.

Who's Affected

OptometristsOphthalmologistsPractice OwnersPatients using OTC eye dropsRetail Pharmacists

What's Next

As this is a developing situation, specific brand names and lot numbers for the eight affected products are expected to be clarified. Clinicians should monitor FDA enforcement reports for a complete list of labels to better advise their patient populations.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.